MedTrace Logo

An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303

NCT03778424 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-07-17

No results posted yet for this study

Summary

This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.

Conditions

  • Lennox Gastaut Syndrome

Interventions

DRUG

Rufinamide

Rufinamide up to 45 milligram per kilogram per day (mg/kg/day).

Sponsors & Collaborators

  • Eisai Inc.

    lead INDUSTRY

Eligibility

Min Age
4 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03778424 on ClinicalTrials.gov